3177 results for «600»
3177 results
The Jon DeHaan Foundation Award competition
19 May 2025 – From EuroPCR 2025
Witness innovation in action at the Jon DeHaan Foundation Award competition featuring groundbreaking technologies like synchronized diaphragmatic stimulation for heart failure and novel devices for aortic bioprosthesis and interatrial shunting.
Invasive treatment of refractory angina
20 May 2025 – From EuroPCR 2025
Explore invasive treatment options for refractory angina through clinical case presentations emphasizing coronary physiology guidance, coronary microvascular disease management, and innovative therapies such as coronary sinus reducer implantation. This session highlights provocative test-guided approaches to optimize patient outcomes.
What is new in atrioventricular valves?
19 May 2025 – From EuroPCR 2025
Discover the latest advancements in atrioventricular valve interventions, including innovative transcatheter repair technologies and first-in-human experiences with novel devices.
Nurses and allied professionals abstracts session
20 May 2025 – From EuroPCR 2025
Highlight the pivotal role of nurses and allied health professionals in interventional cardiology through a series of abstracts addressing radial haemostasis, TAVI nursing programs, early mobilization, radiation protection, and physiologist-led intracoronary thermodilution assessments.
New solutions for old problems
19 May 2025 – From EuroPCR 2025
Discover new solutions addressing persistent cardiovascular challenges, including novel diagnostic systems, vascular closure devices, specialized transcatheter closure technologies, and innovative stent-graft systems.
Complex PCI in calcific coronary artery disease - LIVE Case
20 May 2025 – From EuroPCR 2025
A 76-year-old male patient presented with a significant history of coronary artery disease: CABG with LIMA/LAD and RIMA/OM (1996), RCA PCI with BVS (2016), OM PCI (2017), RIMA occlusion and OM retenosis treated with DCB (2022) with preserved LV. He was admitted for pre-operative evaluation prior...
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
Stable CAD and multivessel disease
20 May 2025 – From EuroPCR 2025
This session delves into the management of stable coronary artery disease (CAD) with multivessel involvement. Learn how clinical and procedural factors influence revascularisation strategies, debate the merits of complete revascularisation, and explore decision-making processes between anatomical and functional approaches through illustrative cases and expert analysis.
Managing TAVI complications
20 May 2025 – From EuroPCR 2025
Gain expertise in managing TAVI complications including strategic retrieval of embolized valves, handling unexpected additional valve usage, managing left ventricle suicide phenomenon, and integrating coronary intervention tools during structural heart procedures, supported by instructive case series.
From crossroads to crossovers: cracking the left main code
20 May 2025 – From EuroPCR 2025
Navigate complex scenarios in left main coronary artery interventions with this session focusing on protected left main and multivessel disease, IVUS-guided PCI, stent optimization, and in-stent restenosis management. Real-world cases from Azerbaijan, Moldova, and Iraq provide collaborative insights and innovative strategies for challenging coronary anatomy.
LAA closure and anthrombotic therapies
21 May 2025 – From EuroPCR 2025
Explore contemporary evidence on left atrial appendage (LAA) closure and associated antithrombotic therapies. This session covers strategies for antithrombotic de-escalation, efficacy and safety in patients with anticoagulation contraindications, breakthrough stroke etiology, and anatomical considerations in high-risk atrial fibrillation patients undergoing ablation.
Updates in transcatheter MVR
21 May 2025 – From EuroPCR 2025
This session provides a detailed overview of recent advances in transcatheter mitral valve replacement (TMVR). Examine outcomes from next-generation transcatheter heart valves, long-term clinical data from mitral valve-in-valve and valve-in-ring procedures, and explore innovative approaches including transseptal MVR with insights from global studies.
Coronary scaffolds: new developments and applications
21 May 2025 – From EuroPCR 2025
Stay informed on advancements in coronary scaffolds with this session reviewing new developments and applications. Topics include comparative performance of magnesium-based bioresorbable stents, long-term clinical outcomes from the BIOMAG-I and FANTOM BRS studies, and real-world experiences with next-generation thin-strut scaffolds.
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)